Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rhophilin-1 is a cytoskeletal adaptor protein encoded by the RHPN1 gene, predominantly known for its interaction with Rho GTPases[1][2][4][5]. It is highly expressed in kidney podocytes, where it regulates actin cytoskeleton dynamics required for maintaining the specialized architecture of podocyte foot processes and the integrity of the glomerular filtration barrier[1][4]. Rhophilin-1 lacks enzymatic activity but functions as a scaffold or effector by relaying or modulating Rho GTPase signaling, particularly influencing actin organization and stress fiber formation[2][4]. Its loss leads to disturbances in cytoskeletal architecture, podocyte effacement, and glomerular pathology including proteinuria and FSGS-like lesions[1]. Genetic alterations are associated with certain spermatogenic defects and rare syndromes[4]. It does not have known small molecule drug modulators or established therapeutic targeting[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rhophilin-1 (RHPN1).